What Happens When You Stop a GLP-1: Data From 638 Posts
We analyzed 638 Reddit posts from people who stopped tirzepatide, semaglutide, or retatrutide. Appetite returns fast, restarting rarely works at the same dose, and the community has reached a clear consensus.
638Posts analyzed
245Regain mentions
133Restart posts
4Subreddits
Disclaimer: This analysis is based on Reddit posts — not a clinical trial. This is not medical advice. Always work with a qualified healthcare provider before changing any medication. Community data reflects self-reported experiences with significant selection bias.
Data scope: Posts collected from r/Retatrutide, r/Zepbound, r/Semaglutide, and r/RetatrutideWomen over 30 days ending March 13, 2026. Tirzepatide is overrepresented (42% of posts) due to r/Zepbound's size; semaglutide is underrepresented relative to real-world prescription share. Drug-specific comparisons should be interpreted with this context in mind.
I stopped retatrutide myself after losing 90 lbs over 11 months. If you want the first-person version of what this data describes — including going off the drug and back on — I documented the whole thing in my retatrutide journey post →
The Three Things That Happen When You Stop
Data from 638 posts across all three drugs — appetite, weight, and mental health
01 — Appetite
236
posts mentioned appetite return. 36% described it as severe. 44 posts reported it returned within days. The most common pattern: food noise is back in 1–2 weeks, at pre-drug intensity by week 3–4.
02 — Weight
245
posts mentioned weight regain. Fastest documented: 26 lbs in under a month, 16 lbs in 3 weeks, 10 lbs in 10 days. 53 posts confirmed regain eventually stabilized.
03 — Mental health
224
posts (35% of all stopping posts) mentioned mental health impact. Fear of regain, anxiety, and food obsession returning were as common as any physical symptom.
"Like many times before, my hunger ramped up. The 'food noise' got loud again, and I felt like I was spiraling out of control as the scale started to tick up."
Appetite Return Severity — 236 Posts That Mentioned It
Severity is self-reported. "Not specified" = mentioned appetite returned but didn't characterize intensity.
Story A: People Who Chose to Stop
140 posts reached goal weight — the hopeful group. The data says most underestimated what came next.
The most optimistic stopping scenario: you hit your goal weight, you've built good habits, you decide to try life without the drug. This represents 140 posts — the second most common stopping reason behind side effects. The data on what happens next is humbling.
Most posts in this group describe the same arc: the first few weeks feel manageable. Then food noise returns gradually. By month 2, the hunger is back at pre-drug intensity. And by month 3–4, the scale is moving in the wrong direction. The "I built habits, I'll be fine" strategy has a name in this dataset — it's the most common regret.
68%
Of restarts are less effective at the same dose
Among the 66 restart posts with definitive outcomes (45 less effective, 22 equally effective, 7 more effective). 67 additional posts were too early to assess. The cycle-on-off strategy specifically: 1 success out of 17 posts that tried it.
"I now realized this medication is pretty much a forever thing if I want to keep the weight off."
Why people stop at goal weight — and why it often fails
The core issue is that GLP-1s treat a chronic condition — they don't cure it. The metabolic and behavioral drivers of weight gain (hunger signaling, food noise, dopamine response to food) return when the drug clears, regardless of how long you were on it. Clinical trial data on semaglutide showed rapid weight regain after cessation regardless of treatment duration — a finding the community cites regularly. Habits built on the drug don't automatically persist without it.
Story B: People Who Were Forced to Stop
120 forced stops — the worst outcomes in the dataset. This is a healthcare access story.
⚠ The insurance/cost crisis: 113 posts (18% of all stopping posts) were driven by insurance loss or cost — people who didn't choose to stop. These posts have the worst regain outcomes in the entire dataset: 49% regain mention rate and the highest rate of ongoing unstabilized regain. One person gained 26 lbs in under a month after insurance cut their Zepbound. These aren't personal failure stories. The system failed these people.
Regain Mention Rate By Stopping Method
Forced stops have the highest regain mention rate and the most unstabilized ongoing regain. Taper had zero posts reporting unstabilized regain — see Section 4.
"As soon as I had to stop Zep the food noise, cravings, hunger pains, binge eating — all the things came back only x10. I lost 128 pounds in about 9 months. After being off the Zep, I gained 26lbs in less than a month. I started smoking again."
"These drugs have made it absolutely clear it was never about self discipline. It was always about how some people literally feel more hunger than others."
Posts often cite multiple reasons; counts reflect all reasons mentioned. "Other" includes travel, supply issues, and unspecified reasons.
How You Stop Matters More Than Whether You Stop
The most actionable finding in the entire dataset
The community has learned something the clinical literature hasn't fully captured yet: the method of stopping dramatically affects what happens next. The data across 638 posts shows a consistent pattern — people who taper slowly have meaningfully better outcomes than people who stop abruptly, regardless of which drug they're on.
Taper method
0
posts with ongoing unstabilized regain
of 33 taper posts mentioning regain, 8 confirmed stabilization
Cold turkey
13
posts with ongoing unstabilized regain
of 25 cold-turkey posts mentioning regain
Important caveat on the taper zero: This is directional, not definitive. People who taper tend to be more planful — they've reached their goal, they have time, they may have medical guidance. People who go cold turkey are more likely to have been forced off or to have stopped abruptly. The taper group is self-selected for better outcomes. But the zero is still striking, and the pattern is consistent across the dataset. Present this finding as a signal, not a guarantee.
"The advice I received is to not taper down to the next dose until hunger signals are leveled out and weight is stable. The first week on 10mg the hunger was fierce but leveled off."
Extracted from 187 taper protocol posts — community-reported, not clinically validated
The most important community rule: don't drop to the next dose until hunger signals are stable and weight is not moving. Some people spend 6 weeks at one dose before stepping down. Calendar-based tapering without this check tends to fail.
From Dose
Step-Down Sequence
Timing Per Step
Alternative: Interval Extension
15 mg
15 → 12.5 → 10 → 7.5 → 5 → 2.5
Monthly when stable
Weekly → every 10d → every 14d
12.5 mg
12.5 → 10 → 7.5 → 5 → 2.5
Monthly when stable
Extend interval before dropping dose
10 mg
10 → 7.5 → 5 → 2.5
Monthly when stable
10mg every 10-12 days is a common maintenance point
7.5 mg
7.5 → 5 → 2.5
4-6 weeks per step
Caution: skipping 5mg to go directly to 2.5 triggers food noise
5 mg
5 → 2.5 → stop or maintain at 2.5
4-6 weeks per step
Many find 2.5mg every 10-14d as long-term floor
⚠ Community-reported only. Not clinically validated. Individual tolerance varies significantly. Work with your prescriber on an exit plan.
The interval extension strategy: Instead of reducing dose, many tirzepatide users extend the injection interval — weekly → every 10 days → every 14 days. This is widely reported as smoother than dose reduction for maintenance, allowing the body to adjust more gradually. Several posts report maintaining weight successfully at 7.5mg or 10mg every 12–14 days for months.
The 2mg threshold: Multiple posts document food noise returning immediately at 2mg after being on higher doses. Many users find 3mg to be the effective maintenance floor — going to 2mg often triggers a hunger rebound within 48 hours. Plan your taper with this threshold in mind.
From Dose
Step-Down Sequence
Timing Per Step
Common Maintenance Landing Point
10–12 mg
10 → 8 → 6 → 4 → 2–3 mg
Monthly per step
2–3 mg/week indefinitely
6–8 mg
6 → 4 → 3 → 2 → 1 mg
Monthly per step
Watch for food noise at 2mg — may need to hold at 3mg
3–4 mg
3 → 2 → 1 mg
4–6 weeks per step
1–2 mg/week maintenance is widely reported
1–2 mg
2 → 1 → 0.5 mg
Monthly per step
0.5–1 mg/week microdose — community endorsed floor
⚠ Community-reported only. Not clinically validated. Gray market retatrutide quality varies — dose precision may differ from pharmaceutical-grade products.
Lilly is studying this formally: TRIUMPH-1 and TRIUMPH-2 specifically include a 4mg maintenance dose arm alongside the 9mg and 12mg weight-loss doses. Results are expected in 2026. The community has been running 1–3mg maintenance empirically — clinical data will soon validate or revise these community-discovered protocols.
Semaglutide has fewer taper-specific posts in this dataset, partly because it's available in fixed pen doses that don't allow fine-grained stepping. The general pattern mirrors tirzepatide — step down one dose level, wait for stability, then move again.
From Dose
Step-Down Sequence
Timing Per Step
Notes
2.4 mg (max)
2.4 → 1.7 → 1.0 → 0.5 → 0.25 mg
Monthly when stable
Fixed pen doses limit flexibility vs compounded options
1.0 mg
1.0 → 0.5 → 0.25 mg or maintain
4–6 weeks per step
0.25mg weekly or bi-weekly used as maintenance floor
0.5 mg
0.5 → 0.25 → stop or maintain
4–6 weeks
Some find even 0.25mg every other week maintains results
⚠ Community-reported only. Not clinically validated.
⚠ GI safety warning on restart: Several posts describe dramatically worse GI side effects when restarting after a break — including one person who restarted at their previous max dose and couldn't keep food down. If you've been off any GLP-1 for more than 2–3 weeks, treat the restart as a fresh titration starting at the lowest dose. Your GI tolerance resets faster than your therapeutic tolerance.
The Restart Myth
68% less effective at the same dose — and cycling doesn't work
The popular mental model: take a break, your tolerance resets, you restart at a lower dose and get the same results. The data says this is wrong for most people.
Among 133 restart posts, 67 are still too early to assess. Of the 66 with definitive outcomes: 45 (68%) less effective, 22 (33%) equally effective, 7 (11%) more effective. The "more effective" group almost always had a specific reason — longer break, different drug, much higher restart dose.
Restart Effectiveness — 66 Posts With Definitive Outcomes
67 additional restart posts were "too early to tell" and are excluded from this chart. Raw counts: 45 less effective, 22 equally effective, 7 more effective.
Why it doesn't work — the community explanation
The mechanism is documented clearly in multiple posts: when you're on a stable dose, the drug is "fully built up" in your system. When you stop and restart at the same dose, it's not fully built up yet — and your tolerance from prior use means you notice the gap immediately. The receptor desensitization that developed during your original course doesn't reset in 2–4 weeks. Most people need to start lower and titrate up again, often needing to reach a higher final dose than before to get equivalent results.
"What happens is someone regularly takes a dose that works for them, say 4mg a week. It's fully built up at that dose. Then they stop. Then they restart at 4mg. It's not fully built up. Then they immediately panic — 'why am I hungrier than before?'"
"I took a break. Not for a reset. For other health reasons. Gained a lot of weight back. Back on sema and titrated to 1.0 and haven't lost any weight since. I weigh more now than when I was on 1.0mg the first time. It doesn't work as well the second time."
Cycling specifically — the data is clear: Of 17 posts specifically about cycling on and off GLP-1s as a strategy, only 1 reported it working as intended. The community's conclusion matches the data: "It's not one of those 'I'll take a break so my tolerance will be lower' type of things." Cycling is the lowest-success maintenance strategy in the dataset.
Story C: What Actually Works for Maintenance
275 posts with maintenance strategies — here's what the data separates out
The community has largely figured this out, and the landing point is consistent: find the lowest dose that holds your results, and stay on it. Not a break. Not a cycle. A floor dose, indefinitely.
Maintenance Strategy — Working vs Not Working
Working/not working based on self-reported outcomes. "Diet/exercise only" likely has significant selection bias — overrepresents highly disciplined users who would have succeeded anyway.
Continued low dose: 78% success rate. 60 working vs 17 not working across 77 posts with reported outcomes. This is the clearest positive finding in the dataset. Community-reported maintenance doses: retatrutide 1–3mg weekly, tirzepatide 2.5–7.5mg weekly or 7.5–10mg every 10–14 days, semaglutide 0.25–0.5mg weekly.
"I told my doc that I am team 'lifetime med' and she was so pleased to hear that."
r/ZepboundMaintenance success
"I am ravenous most days and eat whenever and usually whatever I want — and have maintained a 75 lb weight loss for 22 months. I gauge maintenance on actual maintenance, not side effects like suppression."
Lilly is formally studying the 4mg maintenance dose: TRIUMPH-1 and TRIUMPH-2 are specifically testing 4mg retatrutide as a maintenance arm alongside 9mg and 12mg weight-loss doses. Results are expected in 2026. Citi analysts noted TRIUMPH-1 specifically may hit over 30% weight loss at 80 weeks. The community has been running 1–3mg maintenance empirically — clinical data will soon validate or refine these community-discovered protocols. This is the first time a major Phase 3 program has formally studied a maintenance dose separate from a weight-loss dose.
Community-Reported Maintenance Dose Ranges
Drug
Common Maintenance Dose
Interval
Notes
Retatrutide
1–3 mg
Weekly
2mg threshold — food noise often returns below this. 3mg reported as effective floor by multiple users. Lilly studying 4mg formally.
Tirzepatide
2.5–7.5 mg
Weekly or every 10–14 days
Interval extension often preferred over dose reduction. 5mg weekly or 7.5mg every 12 days cited most frequently.
Semaglutide
0.25–0.5 mg
Weekly or every other week
Fixed pen doses limit flexibility. 0.25mg bi-weekly used as a floor by some.
⚠ Community-reported ranges only. Not clinically validated. Maintenance doses should be discussed with your prescriber.
The Mental Health Burden Nobody Talks About
224 posts (35% of all stopping posts) — this is not a minor footnote
Mental Health Impact Types — 224 Posts
The mental health burden of stopping is as prominent as the physical symptoms, and it runs in two very different directions depending on the drug.
Tirzepatide and semaglutide users stopping posts are dominated by fear of regain and loss of confidence — the mental health burden is about losing the drug, not the drug itself. People grieve access to tirzepatide when insurance cuts it in a way that goes beyond frustration.
Retatrutide users show a different pattern: anhedonia, food obsession returning, and binge urges are more prominent. This is consistent with retatrutide's dopamine-pathway effects — the drug can suppress the reward response to food, and stopping can trigger rebound bingeing or emotional blunting.
"Reta kills the mental reward system through downregulating dopamine — so if you have ADHD then it makes nothing enjoyable if you are on too high of a dose."
"As soon as I stopped, my eating disorder came back very strongly. I started overeating again and gaining weight, and I couldn't continue my fat loss."
The improved mood signal: 19 posts reported better mood after stopping — concentrated in retatrutide. The anhedonia and dopamine suppression that makes reta difficult at high doses means stopping can be a genuine relief for some users. Both directions are real. If you've been experiencing emotional blunting, reduced motivation, or loss of enjoyment on retatrutide, those symptoms may resolve after stopping or dose reduction — typically within 1–2 weeks of the drug clearing.
Drug-Specific Side Effect Stopping Profiles
Why people stop differs significantly by drug — for a deep dive on retatrutide's side effect profile, see our retatrutide side effects guide →
Side Effects Causing Stops — Keyword Frequency in Stop-Reason Details
Keyword mentions in stop-reason detail fields. One post can mention multiple effects. Does not represent incidence rate — represents what people write when they explain why they stopped.
Retatrutide
Stops disproportionately caused by: anhedonia, anxiety, cardiac effects, skin sensitivity. GI effects present but not the primary story. Retatrutide has the highest side-effect stop rate relative to its post share of the three drugs.
Tirzepatide
Stops more evenly distributed across GI effects, fatigue, and hair loss. More likely to stop because things went right (goal reached, insurance lost) than because of intolerable side effects.
Semaglutide
Side effect stops led by GI effects and cost. Cost is the #2 stop reason overall — much more cost-sensitive than the reta/tirz communities in this dataset.
Special Cases: Pregnancy Planning & Surgery
Two scenarios with unique considerations that deserve their own section
Pregnancy planning — 13 posts
A meaningful subset of stops are pregnancy-motivated — women stopping specifically to conceive. One post described getting pregnant within a few months of stopping Zepbound after 2 years of unsuccessful TTC. The data on this is small, but the stakes are high. Key considerations documented in the dataset: most prescribers advise stopping GLP-1s before and during pregnancy; the regain window during TTC and pregnancy is real and difficult to manage; women with PCOS face particular challenges maintaining weight without the drug. If you're planning a pregnancy, discuss your specific timeline and risk profile with your prescriber before stopping. A supervised taper is preferable to abrupt discontinuation.
Surgery prep — 25 posts
Most prescribers and anesthesiologists require GLP-1 discontinuation before surgery due to gastric emptying concerns. The community consensus: disclose proactively and early — don't wait for them to ask. Timing varies by surgeon (most commonly 1–2 weeks for weekly injectables). Plan for potential weight regain during the pre-op and recovery window, particularly for longer surgeries or extended recovery periods. One post gained 17 lbs during a surgical break. Have a restart plan ready before you stop, not after.
Common Questions
From 638 posts across four subreddits
Fast — often within days. Of 236 posts mentioning appetite return, 44 described it as immediate (within days of stopping). Severity was severe in 36% of posts. The most consistent timeline across all three drugs: food noise begins returning in week 1, is moderately disruptive by week 2, and is back at pre-drug intensity by weeks 3–4. The appetite return on retatrutide tends to be more abrupt due to the glucagon mechanism clearing quickly.
No — this is the most common misconception in the dataset. Among 66 restarts with definitive outcomes, 68% were less effective at the same dose. The mechanism: prior GLP-1 exposure desensitizes receptors, and a 4–8 week break doesn't meaningfully reset that. The community consensus is clear — GLP-1s "don't like breaks." If you restart after a break, start lower than your previous dose and titrate up, and expect to need to reach a higher final dose than you used before to get equivalent results.
The data strongly favors a slow taper over cold turkey. Taper-method posts showed zero cases of ongoing unstabilized regain vs 13 for cold turkey. The community protocol: step down one dose level, wait until hunger signals are stable and weight is not moving, then step down again. Don't use a fixed calendar — use stability as the signal. Simultaneously increase calories gradually back to maintenance as you step down doses. Budget 4–6 months for a full taper from max dose to stopping.
This is the worst-outcome scenario in the dataset — forced stops have a 49% regain mention rate and the highest rate of ongoing unstabilized regain. First priority: don't panic. The regain pattern is real but not inevitable. Second: if you can at all access even a maintenance dose (2.5mg tirz, 1mg reta, 0.25mg sema), a floor dose is dramatically better than nothing. Third: compounding options, manufacturer savings programs, and GoodRx can sometimes bridge a coverage gap. Fourth: have a conversation with your prescriber about the regain risk — documenting it may help an insurance appeal. The community has extensive threads on insurance appeals and alternatives worth searching.
67 posts documented side effects resolving after stopping. The patterns: GI effects (nausea, diarrhea, constipation) typically resolve within 1–2 weeks of the drug clearing. Sleep disruption resolves faster — one post confirmed normal sleep within days of stopping. Skin sensitivity (dysesthesia/allodynia) resolves for most within 1–2 weeks. Anhedonia and mood effects are more variable — most posts describe improvement within 2–4 weeks, but some describe longer resolution timelines. Cardiac/elevated heart rate effects appear to resolve relatively quickly with dose reduction or stopping. The one exception: one post described one-sided facial burning that had not resolved 7+ days after stopping — this is atypical and worth medical attention if persistent.
Some people do — 13 working diet/exercise-only maintenance posts vs 2 not working. But this group almost certainly overrepresents exceptionally disciplined individuals. The broader dataset and clinical trial data both point in the same direction: most people regain significant weight within months of stopping, regardless of how long they were on the drug or what habits they built. The community consensus that has emerged across thousands of posts: these drugs treat a chronic condition. For most people, the question isn't "how do I stop" — it's "what's my maintenance dose."
About This Data
How it was collected and what it can and can't tell you
Collection: 638 stopping posts identified from 1,876 total posts scraped from r/Retatrutide, r/Zepbound, r/Semaglutide, and r/RetatrutideWomen over the 30 days ending March 13, 2026. Posts were classified as stopping-related if they described an active, planned, completed, or considered drug discontinuation — not merely comparison questions.
Classification: AI-assisted classification (Claude Sonnet) with outcome coding applied based on OP's stated experience at time of posting. 175 posts returned parsing errors and are excluded from all analysis.
Key limitations: This dataset overrepresents tirzepatide and retatrutide users relative to real-world prescription share due to the subreddits selected. Semaglutide is dramatically underrepresented (12% of posts vs ~70% of prescriptions). Gender was identifiable in ~60% of posts. Reddit posts represent a self-selected, highly motivated population — people post when struggling or celebrating, not when things are quietly fine. The taper zero finding, while striking, reflects a self-selected group of planful users. Forced-stop regain rates reflect a group with uniquely bad circumstances. All findings are directional patterns, not clinical outcomes.
WeightSnap lets you log weights, track progress photos, and see your full timeline — exactly what you need when evaluating whether your maintenance dose is actually holding.